GlassScriptPhysician profile
Wade W Han
NPI 1184638389
$2,940.18
in general payments reported to CMS, 2019-2025
16 companies · $953 in 2025
The $953 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $136 · 2021: $260 · 2022: $375 · 2023: $424 · 2024: $591 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,935 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,935.02 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $956.89 | 2019-2025 | |
| Stryker Corporation | $409.90 | 2019-2025 | Scopis Ent, Audion Et Dilation System, Xpress Loprofile |
| Genzyme Corporation | $376.34 | 2019-2025 | |
| Aerin Medical INC. | $227.06 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $174.07 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $155.73 | 2021-2023 | Nucala |
| Acclarent, INC | $149.71 | 2019-2023 | Trudi Nav Cable |
| Hikma Pharmaceuticals USA | $133.17 | 2023-2025 | Ryaltris |
| Astrazeneca Pharmaceuticals LP | $122.31 | 2025 | |
| Integra Lifesciences Corporation | $83.25 | 2024-2025 | Acclarent Aera, Relieva Spinplus Nav, Trudi Probe |
| Intersect Ent, INC. | $34.41 | 2020-2021 | |
| Amgen INC. | $34.00 | 2025 | |
| Phadia US INC. | $24.51 | 2021 | |
| Neurent Medical Limited | $22.12 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Medtronic, INC. | $19.10 | 2024 | Propel |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $17.61 | 2024 | Tula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.